PMC6861385_01
Histological features of ameloblastoma (A: low magnification, B: high magnification) and BRAF V600E gene mutation assessed by next-generation sequencing (C).
fonc-09-01204-g0001.jpg
PMC6861385_01_fonc-09-01204-g0001.jpg
F1
NCT02534649) and gave also written informed consent for the publication of this case report. Next-generation sequencing of the metastatic tumor sample was performed as previously described and revealed the presence of a BRAF gene V600E mutation [Figure 1; ].
Sustained complete response to dabrafenib + trametinib in a patient with ameloblastoma metastatic to the lungs.
fonc-09-01204-g0002.jpg
PMC6861385_01_fonc-09-01204-g0002.jpg
F2
TEP-CT scan performed 12 weeks after treatment onset showed competed response according to RECIST and PERCIST criteria (Figure 2). The patient is still doing well and in complete remission 30 weeks after treatment initiation.